Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00296816 · ClinicalTrials.gov registry record · Phase 2
TEACO: Taxotere, Eloxatin, Avastin in Cancer of the Ovary
A Phase 2 study of Ovarian Cancer, sponsored by Sanofi.
- Completed
- Registry status
- Phase 2
- Development phase
- 132
- Enrollment target
- 1
- Study location
NCT00296816 is a Phase 2 study of Ovarian Cancer that has completed, run by Sanofi. The registered enrollment target is 132 participants, below the 728-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00296816, a Phase 2 study of Ovarian Cancer, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 132 participants
- Enrollment target
- 1
- Study location
Study Summary
Feasibility study to assess a novel combination of cytotoxic agents, docetaxel and oxaliplatin, as first-line therapy in the treatment of ovarian cancer and the impact of angiogenesis inhibition for the progression and prognosis of ovarian cancer by concurrent addition of bevacizumab (Avastin®).
Conditions Studied
Interventions
- DRUG Bevacizumab (Avastin®)
- DRUG Docetaxel (Taxotere®)
- DRUG Oxaliplatin (Eloxatin®)
Study Locations (1)
New Jersey
- Sanofi-Aventis Administrative Office - Bridgewater
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 132 participants |
| Start Date | 2006-03 |
| Est. Completion | 2011-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00296816
The ClinicalTrials.gov registry entry for NCT00296816 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 132 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 728-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (82% lower). The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Ovarian Cancer appearing as the primary indexed condition, and to 3 interventions - of which Bevacizumab (Avastin®) is the first listed.
NCT00296816 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT00296816 about?
NCT00296816 is a clinical study titled "TEACO: Taxotere, Eloxatin, Avastin in Cancer of the Ovary". Feasibility study to assess a novel combination of cytotoxic agents, docetaxel and oxaliplatin, as first-line therapy in the treatment of ovarian cancer and the impact of angiogenesis inhibition for the progression and prognosis of ovarian cancer by concurrent addition of bevacizumab (Avastin®).
What is the current status of trial NCT00296816?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 132 participants. The study started on 2006-03. Estimated completion is 2011-08.
What conditions does trial NCT00296816 study?
This clinical trial studies the following conditions: Ovarian Cancer.
What interventions are being tested in trial NCT00296816?
The interventions under investigation include: Bevacizumab (Avastin®) (DRUG), Docetaxel (Taxotere®) (DRUG), Oxaliplatin (Eloxatin®) (DRUG).
Who is sponsoring clinical trial NCT00296816?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00296816 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
RECRUITING · Phase 2
-
A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery
RECRUITING · Phase 2
-
Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer
RECRUITING · Phase 2
-
Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Secondary Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Mucinous Ovarian Cancer (HI-MOC Study)
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.